

C
~~immunogenic peptide comprises a sequence selected from the group consisting of SEQ ID NOs: 1-217.~~

8. (new) The composition of claim 7, wherein the sequence is from a cancer-associated antigen and is selected from the group consisting of SEQ ID NOs: 1-43, 99, 170-175, 179, 180, 185-197, and 199-217.

B C
~~9. (new) The composition of claim 8, wherein the cancer-associated antigen is p53 and the sequence is selected from the group consisting of SEQ ID NOs: 4-17, 20-28, 37-43, and 196.~~

10. (new) The composition of claim 9, wherein the sequence is selected from the group consisting of SEQ ID NOs: 4, 5, 7-11, 13, 14, 16, 17, 20-22, 24, 27, 28, 37-43, and 196.

D C
11. (new) The composition of claim 10, wherein the sequence is SEQ ID NO: 4.


12. (new) The composition of claim 8, wherein the cancer-associated antigen is carcinoembryonic antigen (CEA) and the peptide is selected from the group consisting of SEQ ID NOs: 2, 3, 29-36, 99170-175, 179, 194, and 195.

13. (new) The composition of claim 8, wherein the cancer-associated antigen is MAGE and the peptide is selected from the group consisting of SEQ ID NOs: 18, 19, 185, 186, 192, 197, and 200.

D C
14. (new) The composition of claim 8, wherein the cancer-associated antigen is Her2/neu and the peptide is selected from the group consisting of SEQ ID NOs: 180, 187-191, and 199.

15. (new) The composition of claim 8, wherein the cancer-associated antigen is prostate specific membrane antigen (PSM) and the peptide is selected from the group consisting of SEQ ID NOs: 201-217.

16. (new) The composition of claim 7, further comprising a pharmaceutically acceptable carrier.

B!

17. (new) The composition of claim 7, wherein the peptide is linked to a T helper-peptide.

18. (new) The composition of claim 7, wherein the peptide is linked to a lipid.

19. (new) The composition of claim 7, wherein the peptide is linked to a different peptide that induces a cytotoxic T lymphocyte response.

20. (new) The composition of claim 7, further comprising a liposome.

21. (new) The composition of claim 7, wherein the peptide is complexed with an HLA-A2.1 molecule that is present on an antigen-presenting cell

22. (new) The composition of claim 21, wherein the antigen-presenting cell is a dendritic cell.

REMARKS

1. Status of the claims

With entry of the present amendment, claim 1 is canceled and new claims 7-22 are added.

Claim 7 recites an immunogenic peptide of less than about 15 amino acids in length, and a sequence selected from the group consisting of SEQ ID NOs: 1-217. This